SCHEDULE: OrbiMed Advisors Reports 8% Stake in NeuroPace Inc.

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have jointly reported an 8% beneficial ownership stake in NeuroPace Inc.'s common stock.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, both Delaware entities, have filed an Amendment No. 6 to their Schedule 13G.
• The filing reports their beneficial ownership of 2,614,184 shares of NeuroPace Inc. Common Stock, representing 8% of the class.
• The reported ownership is as of June 30, 2025, with the filing signed on August 14, 2025.
• OrbiMed Advisors LLC is classified as an Investment Adviser (IA), while OrbiMed Capital GP VI LLC is classified as 'Other' (OO).
• Both entities share voting and dispositive power over all 2,614,184 shares.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of NeuroPace Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing is primarily a factual disclosure of beneficial ownership. The continued significant stake by a specialized healthcare investor like OrbiMed can be viewed as a moderately positive signal of confidence in NeuroPace Inc., though it does not provide new performance data.

Positives

• A significant 8% beneficial ownership stake by OrbiMed, a prominent healthcare-focused investment firm, indicates continued institutional interest and confidence in NeuroPace Inc.

Negatives

• NA

Risks

• The filing itself does not detail specific company risks, but rather discloses beneficial ownership. General risks associated with significant institutional ownership include potential large-scale selling if the investor's strategy changes, which could impact stock price.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding NeuroPace Inc.'s future performance or strategic outlook.

Industry Context

OrbiMed's continued significant stake in NeuroPace Inc. highlights ongoing investor interest in the medical device and neuroscience sectors, particularly in companies developing therapies for neurological disorders.

Stakeholder Impact

• Shareholders: The disclosure of a significant 8% stake by a major institutional investor like OrbiMed may influence investor perception and potentially provide a degree of stability or confidence in the stock. It also indicates a substantial portion of the company's shares are held by a single investment group.

Key Dates

Recommendation

This Schedule 13G filing is a disclosure of beneficial ownership and does not provide sufficient financial or operational data to warrant a 'buy' or 'sell' recommendation. While OrbiMed's significant stake suggests institutional confidence, a comprehensive investment decision requires analysis of NeuroPace Inc.'s financial performance, strategic initiatives, and market conditions beyond this ownership report.

Keywords

NeuroPace Inc, OrbiMed Advisors, OrbiMed Capital, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Healthcare Investment, Medical Devices